The efficacy of human epidermal growth factor receptor 2 (HER2) blockade switching mode in refractory patients with HER2-positive metastatic breast cancer: a phase II, multicenter, single-arm study (SYSUCC-005)

BACKGROUND: Despite significant survival improvement in human epidermal growth factor receptor 2 (HER2) blockade for HER2-positive breast cancer, resistance to anti-HER2 remains inevitable. Subsequent anti-HER2 with continuing trastuzumab beyond progression is acceptable with limited efficacy when o...

Descripción completa

Detalles Bibliográficos
Autores principales: Duan, Fangfang, Zhong, Muyi, Ma, Yuyu, Song, Chenge, Zhang, Lehong, Lin, Ying, Wu, Zhiyong, Zhang, Yuanqi, Huang, Jiajia, Xu, Fei, Shi, Yanxia, Wang, Shusen, Yuan, Zhongyu, Xia, Wen, Bi, Xiwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922887/
https://www.ncbi.nlm.nih.gov/pubmed/35291977
http://dx.doi.org/10.1186/s12885-022-09399-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8922887/
https://www.ncbi.nlm.nih.gov/pubmed/35291977
http://dx.doi.org/10.1186/s12885-022-09399-2

Ejemplares similares